- Anixa Biosciences (ANIX, Financial) to present at H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025.
- The event will be held at Nasdaq World Headquarters in New York City, with a webcast available for remote access.
- Mike Catelani, President and CFO, will represent Anixa and engage in one-on-one meetings with investors.
Anixa Biosciences (ANIX), a biotechnology company focused on the treatment and prevention of cancer, is set to participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. This key industry event will take place on May 20, 2025, at the prestigious Nasdaq World Headquarters in New York City. Mike Catelani, President and CFO of Anixa, will present at 11:00 AM ET and engage in one-on-one meetings with investors. This participation underscores Anixa's commitment to increasing its visibility among the investment community and highlighting its advancements in cancer-focused biotechnology.
Investors and interested parties can access the presentation through a webcast link provided by the company, ensuring that Anixa's innovative developments reach a global audience. Anixa Biosciences is renowned for its ovarian and breast cancer vaccine programs, developed in collaboration with top-tier institutions like the Moffitt Cancer Center and Cleveland Clinic. These initiatives leverage cutting-edge chimeric endocrine receptor-T cell (CER-T) technology and focus on immunizing against proteins associated with various cancers.
This appearance at the BioConnect Conference presents a significant opportunity for Anixa (ANIX, Financial) to showcase its robust pipeline and strategic collaborations, further establishing its position as a leader in cancer biotechnology.
